相关实验视频

Updated: May 24, 2025

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

小分子LpxC抑制剂对抗グラム阴性细菌的最新进展 (2014-2024)

Pengpeng Ji¹, Meng Ma¹, Xiaoyue Geng¹

¹School of Pharmacy, Shandong Second Medical University, Weifang, Shandong, China.

Frontiers in microbiology

|March 5, 2025

概括

耐多药格拉姆阴性细菌是全球健康的威胁. 本综述检查了小分子LpxC抑制剂,重点关注结构,功能和毒性,以指导未来的药物开发对抗这些具有挑战性的病原体.

科学领域:

微生物学微生物学
药用化学医学化学
药物发现药物发现药物发现

背景情况:

世界卫生组织 (WHO) 已将多药耐药 (MDR) 格拉姆阴性细菌确定为严重的公共卫生威胁.
这些细菌负责越来越多的难以治疗的感染.
尿素二酸-3-O- ((hydroxymyristoyl) -N-乙糖胺脱乙酸酶 (LpxC) 是一种酶,对格拉姆阴性细菌的外膜合成至关重要,是有前途的药物标.

研究的目的:

审查最近在开发小分子LpxC抑制剂方面的进展.
分析LpxC抑制剂的结构-活性关系和构造方面.
讨论动物毒性数据及其对临床翻译的影响.

主要方法:

在过去10年中发表的小分子LpxC抑制剂的文献综述,重点是过去5年.
分析结构变化及其对抑制活性的影响.
评估临床前安全性和毒性数据.

主要成果:

已经合成了许多小分子LpxC抑制剂,包括L-573,655,TU-514,CHIR-090,ACHN-975和TP0586532.等值得注意的例子.
尽管有前临床数据很有希望,但只有ACHN-975在因安全问题而停止治疗之前,才达到I期临床试验.
临床试验的有限成功凸显了LpxC抑制剂开发的挑战,特别是关于安全性和有效性的挑战.

结论:

对于新型抗生素来说,LpxC仍然是一个有效的和有吸引力的目标,用于对抗MDR格兰氏阴性细菌.
对结构优化和综合性毒性分析进行进一步的研究对于成功的临床开发至关重要.
了解形状动态和提高安全性是推动LpxC抑制剂作为可行的治疗选择的关键.

关键词:

CHIR-09090 的意思是什么?LpxC 抑制剂的使用 TP 058653232 这是一个很棒的项目.格拉姆阴性细菌是一种细菌.多抗药性 (MDR) 是指多抗药性.

更多相关视频

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing

Published on: July 7, 2020

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Genomic DNA in Prokaryotes

Genomic DNA in Prokaryotes

The genome of most prokaryotic organisms consists of double-stranded DNA organized into one circular chromosome in a region of cytoplasm called the nucleoid. The chromosome is tightly wound, or supercoiled, for efficient storage. Prokaryotes also contain other circular pieces of DNA called plasmids. These plasmids are smaller than the chromosome and often carry genes that confer adaptive functions, such as antibiotic resistance.
Genomic Diversity in Bacteria
Although bacterial genomes are much...